|
TOP NEWS
Takeda Says Rebates, Subsidies Cut $885M IBS Drug Verdict
By Bryan Koenig
Takeda Pharmaceuticals battled with a class of health plans over whether a Massachusetts federal jury's $885 million antitrust verdict against the drugmaker for conspiring to delay generic competition to anticonstipation drug Amitiza should be reduced by rebates the drugmaker paid and Medicare subsidies that reduced the health plans' costs.
2 documents attached |
Read full article »
| Save to favorites »
EMPLOYMENT & BENEFITS
SECURITIES
Panel Rejects BMS Investor's Bid To 'Camouflage A Wolf'
By George Woolston
A New Jersey state appeals court said an investor's amended complaint over Bristol-Myers Squibb Co.'s $74 billion acquisition of Celgene Corp. was a wolf camouflaged in sheep's clothing, finding that the investor's claims of disclosure requirement shortfalls sounded more in fraud than negligence and failed to satisfy the heightened pleading standard required.
Opinion attached |
Read full article »
| Save to favorites »
COMPETITION
PRODUCT LIABILITY
Glenmark Pharma Hit With Safety Suit After Carvedilol Recalls
By Craig Clough
Glenmark Pharmaceuticals' generic drug carvedilol, used to treat high blood pressure and congestive heart failure, was misrepresented as therapeutically equivalent to the brand-name drug Coreg but contained undisclosed nitrosamine impurities that changed its strength, quality and safety profile, according to a proposed class action filed Tuesday in Washington federal court.
Complaint attached |
Read full article »
| Save to favorites »
CYBERSECURITY & PRIVACY
CONSUMER PROTECTION
REAL ESTATE
SPORTS & BETTING
EXPERT ANALYSIS
LEGAL INDUSTRY
Simpson Thacher Witness Takes Aim At PIPE Stocks Claim
By Madison Arnold
Simpson Thacher & Bartlett LLP wrapped up its defense Wednesday to a Florida state malpractice suit from the founder of Patriot National Inc. over the firm's handling of a private investment in public equity transaction, with a stock market expert testifying that short selling stock allowed under the deal didn't lead to the insurance services company's downfall.
Read full article »
| Save to favorites »
|